Vita Imaging Wins ISO 13485 Approval for Skin Cancer Detection Tech

Vita Imaging said Aug. 10 it received ISO 13485 certification from the British Standards Institution, a major step toward regulatory approvals and commercialization of its AURA skin cancer detection platform. The company says the milestone moves its noninvasive technology closer to CE Mark review in Europe and future market launch.

Why it matters: - ISO 13485 certification is a key quality-system benchmark for medical technology companies seeking regulatory approvals and commercial manufacturing. - The approval strengthens Vita Imaging's path to market for AURA, a noninvasive skin cancer detection platform aimed at helping physicians make faster, more informed decisions. - The milestone could support future partnerships and global expansion as the company advances toward commercialization.

What happened: - Vita Imaging announced on Aug. 10 that it received ISO 13485 certification from the British Standards Institution. - The company said the certification validates its quality management system for designing, developing and manufacturing medical technology. - Vita Imaging said the certification advances AURA toward regulatory approvals and a future market launch.

The details: - AURA is designed to help physicians evaluate suspicious skin lesions in under 1.5 seconds. - The platform uses proprietary Raman spectroscopy technology. - Vita Imaging said the device provides clinicians with additional objective information during patient examinations. - The company said AURA may improve diagnostic confidence, support more informed biopsies and improve the patient experience. - BSI is a globally recognized Notified Body under the European Union Medical Device Regulation. - BSI will serve as Vita Imaging's regulatory partner as the company pursues CE Mark certification for AURA in Europe. - Vita Imaging said the certification provides a foundation for regulatory approvals, commercial manufacturing, strategic partnerships and future global expansion. - The company said the milestone builds on more than two decades of research and development. - Vita Imaging's flagship technology is a patented, noninvasive device aimed at the early detection of precancerous and malignant tumors. - Vita Imaging says AURA helps physicians evaluate suspicious skin lesions in real time by providing objective diagnostic information during patient examinations.

Between the lines: - The certification matters because medical-device commercialization often hinges on quality-system readiness, not just product performance. - Vita Imaging is signaling that AURA is moving from research and validation toward the operational requirements needed for broader clinical and market deployment. - The European regulatory path appears to be a near-term focus, with CE Mark review tied to BSI's role under EU MDR.

What's next: - Vita Imaging said it will continue pursuing regulatory approvals for AURA. - The company said it is preparing for commercial manufacturing and market introduction. - Future progress will likely center on CE Mark certification in Europe and broader commercialization steps.

The bottom line: - ISO 13485 certification gives Vita Imaging a critical green light for the next phase of bringing AURA to market.